By VETTAPHARMA reporter: Takeda has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861), an investigational oral orexin receptor 2 (OX2R)-selective agonist intended for the treatment of narcolepsy type 1 (NT1). This development represents a significant regulatory milestone in the company’s efforts to address a major unmet need in this chronic neurological condition.
Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date in the third quarter of 2026, meaning a final decision on potential approval could occur during that period. Priority Review status is granted to applications that, if approved, could offer significant improvements in safety or effectiveness compared with existing therapies.
Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. NT1 is characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone), among other debilitating symptoms that affect physical, cognitive, and social functioning. Despite the availability of symptomatic treatments, many patients continue to experience persistent symptoms, highlighting the ongoing need for novel therapeutic options.
According to Takeda, the NDA submission is supported by a comprehensive data package from the global FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) Phase 3 studies. These trials measured both objective and patient-reported outcomes including wakefulness, excessive daytime sleepiness, cataplexy frequency, ability to maintain attention, overall quality of life, and daily life functioning. The company reports that oveporexton demonstrated statistically significant and clinically meaningful improvements, with many measures reaching near normal ranges across the broad range of symptoms investigated.
Oveporexton was generally well-tolerated in clinical studies, with the most common adverse events including insomnia, urinary urgency, and urinary frequency. The safety profile was consistent with previous clinical experience.
In addition to its U.S. regulatory progress, oveporexton previously received Breakthrough Therapy designation from the FDA for the treatment of excessive daytime sleepiness in NT1 and Sakigake designation from the Japanese Ministry of Health, Labour and Welfare, underscoring its potential to transform current NT1 treatment paradigms.
Takeda remains on track to potentially deliver the first approved orexin agonist therapy to people living with NT1 and continues to advance its broader orexin science portfolio, which includes additional investigational orexin agonists in development.
Source credit:
- Takeda Pharmaceuticals. (2026, February 10). U.S. Food and Drug Administration accepts New Drug Application and grants priority review for Takeda’s Oveporexton (TAK-861) as a potential first-in-class therapy for narcolepsy type 1. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
